Knoxville, TN, UNITED STATES--April 7th, 2014 – ABT Molecular Imaging has successfully implemented the first BG-75 Biomarker Generator in Russia. The project was completed in cooperation with the Diagnostic and Treatment Center of the International Institute of Biological Systems (DTC IIBS), St. Petersburg, Russia, and its U.S. representative, Owen Kane Molecular Imaging, Inc. (Owen Kane).
The BG-75 Biomarker Generator integrates a compact cyclotron, micro-chemistry and automated quality control to provide single-dose, on-demand F-18 FDG production in one seamless solution.
DTC IIBS is the leading provider of diagnostic services in the Russian Federation, with a network of 80 diagnostic centers located in more than 60 cities in Russia.
The Biomarker Generator system is in full clinical use, providing in-house production of F-18 FDG. This allows the oncologists in the Center to get necessary information about the current progress of disease, evaluate the treatment outcome and adjust individual cancer treatment plans accordingly. The PET study can be scheduled and performed without any waiting time or relocation to another facility.
The system is installed at a new, state-of-the-art oncology center, the Center of Radiosurgery, Stereotactic Radiotherapy and Oncology, providing comprehensive cancer care to the region. The Center is equipped with the Gamma Knife (Elekta), Cyber Knife (Accuray) and TrueBeam STX (Varian) therapy units.
“We are very proud of our relationship with DTC IIBS, and truly excited that we are a part of their expansion in Molecular Imaging,” said Peter Kingma, President and CEO of ABT Molecular Imaging. “We believe that our BG-75 is particularly well matched to the growing clinical demands of Russia, and look forward to supporting this innovative company as it continues to expand in the future.”
Dr. Arkadi Stolpner, Chief Executive Officer of DTC IIBS, and Mr. Philip F. Jacobus of Owen Kane expressed that the ABT BG-75 is uniquely suited for the Russian market.
About ABT Molecular Imaging, Inc.:
ABT Molecular Imaging is a medical imaging company marketing the BG-75 Biomarker Generator, which produces unit doses of molecular imaging drugs for positron emission tomography (PET) at the point of use. The company was founded in 2006 by industry experts in the molecular imaging industry. ABT’s investor partners include Intersouth Partners, River Cities Capital and two TNInvestco Funds, Council & Enhanced Tennessee Fund and Limestone Fund. The Company is headquartered in Knoxville, Tennessee. For more information, visit www.advancedbiomarker.com.